MHRA Approves Wegovy for MASH Liver Disease in UK

On Friday 3 July 2026, the MHRA approved semaglutide (Wegovy) for adults with metabolic-associated steatohepatitis, or MASH, who have moderate-to-advanced liver fibrosis. That is a significant regulatory step, but it does not mean patients can already get the treatment on the NHS for MASH. (gov.uk) If you have seen the word "approved" and assumed "available", this is the first distinction to hold on to. The MHRA decides whether a medicine can be authorised as acceptably safe and effective, while NICE decides whether it should be recommended in the NHS after looking at clinical evidence and cost effectiveness. (gov.uk)

MASH is a serious stage of fatty liver disease. In simple terms, fat builds up in the liver, then starts to trigger inflammation and scarring; over time, that scarring can worsen. NHS and NHS trust information explains that fatty liver disease can progress from fat build-up to steatohepatitis, then fibrosis, and in some people to cirrhosis and other major complications. (gov.uk) You are more likely to develop this kind of liver disease if you live with obesity, type 2 diabetes, high cholesterol or related metabolic conditions. One reason the story matters is that liver damage can be developing even when symptoms are mild or easy to miss. (gov.uk)

Semaglutide belongs to a group of medicines called GLP-1 receptor agonists. In everyday language, that means it copies the action of a hormone released after eating, helping people feel fuller for longer; NHS guidance also notes that semaglutide is already used for obesity and type 2 diabetes, depending on the brand and indication. (gov.uk) So this is not a completely new medicine arriving out of nowhere. What is new is the liver disease use. Semaglutide already had UK authorisations linked to weight management and, for some adults, cardiovascular risk reduction, and the MHRA has now added MASH for a defined group of patients. (gov.uk)

The approval comes with an important footnote. The MHRA says semaglutide has been given a conditional marketing authorisation for MASH, which means more confirmatory evidence from an ongoing study still has to be submitted before a full marketing authorisation can be considered. (gov.uk) That does not mean the medicine has been waved through without scrutiny. A conditional authorisation is used when the regulator judges that the balance of benefits and risks is positive, that there is an unmet medical need, and that fuller data should become available soon enough to test the decision properly. The MHRA says it will review new information on semaglutide at least every year. (gov.uk)

Here is the part many headlines leave out. Patients with MASH cannot currently get semaglutide on the NHS for this condition, because NICE is still appraising it. NICE's project page says the appraisal remains in progress, the expected publication date is still 'TBC', and the process was delayed following a request from the company. (nice.org.uk) NICE also says this work is a single technology appraisal, which means it is weighing the clinical evidence and the cost effectiveness before deciding whether the medicine should be recommended in the NHS. As of 5 July 2026, the provisional schedule shows a first committee meeting on 15 October 2026. (nice.org.uk)

For readers wondering what treatment looks like in practice, this is a weekly injection that starts low and rises step by step. The MHRA says the dose begins at 0.25 mg once weekly, then moves through 0.5 mg, 1 mg and 1.7 mg, with four weeks on each dose before the maintenance dose of 2.4 mg once weekly. (gov.uk) The release also says that for patients with obesity, defined there as a BMI over 30, the dose can rise to 7.2 mg weekly after at least four weeks on 2.4 mg. But the teaching point here is simple: this is a prescription-only medicine, the dosing is clinician-led, and it is meant to be used alongside diet and exercise rather than as a stand-alone fix. (gov.uk)

Semaglutide is not an over-the-counter answer, and the side effects matter. The MHRA lists the most common problems as gastrointestinal effects including nausea, diarrhoea, constipation and vomiting, while NHS advice makes clear that semaglutide is only available with a prescription. (gov.uk) If someone thinks they are having a side effect, the MHRA says they should speak to a doctor, pharmacist or nurse and can also report it through the Yellow Card scheme. That reminder matters because safety monitoring does not stop on approval day; it continues after a medicine reaches real patients. (gov.uk)

**What this means:** the UK regulator has opened the door to semaglutide as a treatment for a serious form of fatty liver disease, but the NHS funding and access question is still unresolved. For patients, the next major moment is not another approval headline but the NICE decision on whether the treatment should be routinely available for this use. (gov.uk) That may sound procedural, but it shapes real life. In the UK system, approval answers "can this medicine be licensed?", while NICE appraisal answers "should the NHS pay for it here, for these patients, on this evidence?" If you want to read this story clearly, that is the line worth watching. (gov.uk)